SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2013 / Cilt: 13 - Sayı: 2

Can nebivolol be helpful in Behçet’s disease?

Behçet hastalığına nebivolol yararlı olabilir mi?

Antonella TOMMASİNO
Giovan Battista MAURO
Pages
121–122
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

TOMMASİNO, A., MAURO, G. B. (2022). Can nebivolol be helpful in Behçet’s disease?. Anadolu Kardiyoloji Dergisi, Cilt: 13 - Sayı: 2, 121–122. https://ajindex.com/articles/436296

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999
  2. [CrossRef] 2. Koç Y, Güllü I, Akpek G, Akpolat T, Kansu E, Kiraz S, et al. Vascular involvement in Behçet's disease. J Rheumatol 1992
  3. Köse O. Development of immunopathogenesis strategies to treat Behçet's disease. Patholog Res Int 2012
  4. 261989. 4. Kapsimali VD, Kanakis MA, Vaiopoulos GA, Kaklamanis PG. Etiopathogenesis of Behçet's disease with emphasis on the role of immunological aberrations. Clin Rheumatol 2010
  5. [CrossRef] 5. Mendoza-Pinto C, García-Carrasco M, Jiménez-Hernández M, Jiménez Hernández C, Riebeling-Navarro C, Nava Zavala A, et al. Etiopathogenesis of Behçet's disease. Autoimmun Rev 2010
  6. [CrossRef] 6. Jorizzo JL, Abernethy JL, White WL, Mangelsdorf HC, Zouboulis CC, Sarıca R, et al. Mucocutaneous criteria for the diagnosis of Behçet's disease: an analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol 1995
  7. [CrossRef] 7. Freitas JP Filipe P Yousefi A, Emerit I, Guerra Rodrigo F. Oxidative stress in Adamantiades-Behçet's disease. Dermatology 1998
  8. [CrossRef] 8. Ozoran K, Düğün N, Gürler A, Tutkak H, Tokgöz G. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen acti- vator inhibitor, and antithrombin III levels in Behçet's disease. Scand J Rheumatol 1995
  9. [CrossRef] 9. Hampton KK, Chamberlain MA, Menon DK, Davies JA. Coagulation and fibrinolytic activity in Behçet's disease. Thromb Haemost 1991
  10. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial func- tion and oxidative stress mechanisms in patients with Behçet's syndrome. J Am Coll Cardiol 2001
  11. [CrossRef] 11. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and per- oxynitrite: the good, the bad, and ugly. Am J Physiol 1996
  12. C1424-37. 12. Karakaş MS, Akkaya H, Şahin Ö, Borlu M, Oğuzhan A. Effect of nebivolol on endothelial dysfunction in patients with Behçet’s dis- ease
  13. a prospective single-arm controlled study. Anadolu Kardiyol Derg 2013
  14. Toblli JE, DiGennaro F, Giani JF, Dominici FP Nebivolol: impact on cardiac and endothelial function and clinical utility. Vasc Health Risk Manag 2012
  15. [CrossRef] 14. Rozec B, Gauthier C. Beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther 2006
  16. [CrossRef] 15. Ignarro LJ. Different pharmacological proper